Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Related Clinical Trial
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia AML Therapy With Irradiated Allogeneic Cells Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Genetic and Molecular Characteristics of Mexican Adults With Acute Myeloid Leukemia: a Prospective Multicentric Study. Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML)

Brief Title

Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Official Title

Phase III Study of MDR Modulation With PSC-833 (NSC #648265) Followed by Immunotherapy With rIL-2 (NSC #373364) vs. No Further Therapy in Previously Untreated Patients With AML >60 Years

Brief Summary

      Randomized phase III trial to compare the effectiveness of combination chemotherapy with or
      without PSC 833 followed by interleukin-2 or no further therapy in treating older patients
      who have acute myeloid leukemia. Some cancers become resistant to chemotherapy drugs.
      Combining PSC 833 with more than one chemotherapy drug may reduce resistance to the drugs and
      allow the cancer cells to be killed. Combining interleukin-2 with combination chemotherapy
      plus PSC 833 may kill more cancer cells.
    

Detailed Description

      PRIMARY OBJECTIVES:

      I. To determine whether the addition of PSC-833 to induction chemotherapy improves complete
      response rates and whether the addition of PSC-833 to induction and consolidation
      chemotherapy improves survival for patients with AML >= 60 years.

      II. To determine whether the administration of low-dose, subcutaneous rIL-2 immunotherapy
      with intermittent high-dose boluses after chemotherapy prolongs disease-free survival.

      OUTLINE: This is a partially randomized, multicenter study. Patients are stratified according
      to participating center and disease characteristics (de novo acute myeloid leukemia (AML)
      versus AML with antecedent myelodysplasia). Patients are randomized to one of two maintenance
      therapy arms.

      Arm I: Patients receive cytarabine IV continuously over 7 days and daunorubicin IV bolus
      followed by etoposide IV over 2 hours on days 1-3.

      Arm II: Patients receive treatment as in arm I with the addition of PSC 833 induction. A
      loading dose of PSC 833 IV is given over 2 hours, followed by a 74-hour continuous infusion
      of PSC 833 beginning 2 hours before daunorubicin and etoposide. Patients may receive a second
      induction course if residual leukemia is present in the bone marrow. Patients who experience
      a complete remission (CR) and meet certain other criteria receive postremission chemotherapy
      consisting of cytarabine IV continuously over 5 days plus daunorubicin IV followed by
      etoposide IV over 2 hours on days 1 and 2. Patients who are randomized to receive PSC 833
      during induction chemotherapy receive a loading dose of PSC 833 before beginning a 48-hour
      continuous infusion of PSC 833 concurrently with cytarabine/daunorubicin/etoposide
      postremission chemotherapy.

      After completing postremission chemotherapy, patients are randomized to a no further
      treatment group or interleukin-2 (IL-2) immunotherapy. Treatment begins within 5 months of
      postremission chemotherapy. IL-2 immunotherapy consists of low-dose subcutaneous (SC) IL-2 on
      days 1-14, 19-28, 33-42, 47-56, 61-70, and 75-90 and high-dose bolus SC IL-2 on days 15-17,
      29-31, 43-45, 57-59, and 71-73.

      Patients are followed every 2 months for 2 years, every 6 months for 2 years, annually until
      the tenth year, and then at relapse.
    

Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

Disease-free survival


Condition

Adult Acute Megakaryoblastic Leukemia (M7)

Intervention

cytarabine

Study Arms / Comparison Groups

 Arm I (cytarabine, daunorubicin, etoposide)
Description:  Patients receive cytarabine IV continuously over 7 days and daunorubicin IV bolus followed by etoposide IV over 2 hours on days 1-3.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

640

Start Date

January 1998


Primary Completion Date

August 2002

Eligibility Criteria

        Inclusion Criteria:

          -  Unequivocal histologic diagnosis of AML, FAB classification (M0-M7), excluding M3
             (acute promyelocytic leukemia); patients with a history of antecedent myelodysplasia
             remain eligible for treatment on this trial

          -  No prior treatment for acute leukemia or myelodysplasia with four permissible
             exceptions:

               -  Emergency leukapheresis;

               -  Emergency treatment for hyperleukocytosis with hyroxyurea;

               -  Cranial RT for CNS leukostasis (one dose only);

               -  Growth factor/cytokine support.
      

Gender

All

Ages

60 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Maria Baer, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT00003190

Organization ID

NCI-2012-02793

Secondary IDs

CALGB-9720

Responsible Party

Sponsor

Study Sponsor

National Cancer Institute (NCI)


Study Sponsor

Maria Baer, Principal Investigator, Cancer and Leukemia Group B


Verification Date

June 2013